drugset / Trial / NCT00162253

Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

NCT00162253 ↗

Phase 2 Terminated 120 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.

Timeline

Start
2005-04
Primary completion
2006-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS 587101 Unknown — —

Indications